Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: One year follow-up study

Vicenç Falcó; Queralt Jordano; María Jesús Cruz; Oscar Len; Esteve Ribera; Magda Campins; Manel Crespo; Inma Ocaña; María José Rodrigo; Albert Pahissa

doi:10.1016/j.vaccine.2005.12.021

Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: One year follow-up study

Vicenç Falcó, Queralt Jordano, María Jesús Cruz, Oscar Len, Esteve Ribera, Magda Campins, Manel Crespo, Inma Ocaña, María José Rodrigo, Albert Pahissa

Research output: Contribution to journal › Article › Research › peer-review

37 Citations (Scopus)

Abstract

The aim of this study was to evaluate specific IgG responses against pneumococcal serotypes 1, 6B, 14, 19F, 23F at baseline, 1 and 12 months after vaccination with the 23-valent polysaccharide pneumococcal vaccine in 89 HAART-treated HIV-infected patients, 24 antiretroviral "naïve" HIV-infected and 30 non-HIV-infected healthy subjects. Levels of specific antipneumococcal IgG and the mean fold increase in IgG levels at 1 month as well as the kinetics of antibodies along the 12 months in all groups of HIV-infected patients and healthy subjects were similar. Neither CD4 cell count at baseline nor "nadir" CD4 cells correlated with the response to the vaccine. In conclusion, the immunogenicity conferred by the polysaccharide vaccine in HIV-infected patients under HAART is at least as good as that observed in healthy subjects. © 2005 Elsevier Ltd. All rights reserved.

Original language	English
Pages (from-to)	2567-2574
Journal	Vaccine
Volume	24
Issue number	14
DOIs	https://doi.org/10.1016/j.vaccine.2005.12.021
Publication status	Published - 24 Mar 2006

Keywords

HIV infection
Pneumococcal polysaccharide vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2005.12.021

Cite this

@article{dd5ca6e164564a768ecd0cdb38a0c75b,

title = "Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: One year follow-up study",

abstract = "The aim of this study was to evaluate specific IgG responses against pneumococcal serotypes 1, 6B, 14, 19F, 23F at baseline, 1 and 12 months after vaccination with the 23-valent polysaccharide pneumococcal vaccine in 89 HAART-treated HIV-infected patients, 24 antiretroviral {"}na{\"i}ve{"} HIV-infected and 30 non-HIV-infected healthy subjects. Levels of specific antipneumococcal IgG and the mean fold increase in IgG levels at 1 month as well as the kinetics of antibodies along the 12 months in all groups of HIV-infected patients and healthy subjects were similar. Neither CD4 cell count at baseline nor {"}nadir{"} CD4 cells correlated with the response to the vaccine. In conclusion, the immunogenicity conferred by the polysaccharide vaccine in HIV-infected patients under HAART is at least as good as that observed in healthy subjects. {\textcopyright} 2005 Elsevier Ltd. All rights reserved.",

keywords = "HIV infection, Pneumococcal polysaccharide vaccine",

author = "Vicen{\c c} Falc{\'o} and Queralt Jordano and Cruz, {Mar{\'i}a Jes{\'u}s} and Oscar Len and Esteve Ribera and Magda Campins and Manel Crespo and Inma Oca{\~n}a and Rodrigo, {Mar{\'i}a Jos{\'e}} and Albert Pahissa",

year = "2006",

month = mar,

day = "24",

doi = "10.1016/j.vaccine.2005.12.021",

language = "English",

volume = "24",

pages = "2567--2574",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "14",

}

TY - JOUR

T1 - Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: One year follow-up study

AU - Falcó, Vicenç

AU - Jordano, Queralt

AU - Cruz, María Jesús

AU - Len, Oscar

AU - Ribera, Esteve

AU - Campins, Magda

AU - Crespo, Manel

AU - Ocaña, Inma

AU - Rodrigo, María José

AU - Pahissa, Albert

PY - 2006/3/24

Y1 - 2006/3/24

N2 - The aim of this study was to evaluate specific IgG responses against pneumococcal serotypes 1, 6B, 14, 19F, 23F at baseline, 1 and 12 months after vaccination with the 23-valent polysaccharide pneumococcal vaccine in 89 HAART-treated HIV-infected patients, 24 antiretroviral "naïve" HIV-infected and 30 non-HIV-infected healthy subjects. Levels of specific antipneumococcal IgG and the mean fold increase in IgG levels at 1 month as well as the kinetics of antibodies along the 12 months in all groups of HIV-infected patients and healthy subjects were similar. Neither CD4 cell count at baseline nor "nadir" CD4 cells correlated with the response to the vaccine. In conclusion, the immunogenicity conferred by the polysaccharide vaccine in HIV-infected patients under HAART is at least as good as that observed in healthy subjects. © 2005 Elsevier Ltd. All rights reserved.

AB - The aim of this study was to evaluate specific IgG responses against pneumococcal serotypes 1, 6B, 14, 19F, 23F at baseline, 1 and 12 months after vaccination with the 23-valent polysaccharide pneumococcal vaccine in 89 HAART-treated HIV-infected patients, 24 antiretroviral "naïve" HIV-infected and 30 non-HIV-infected healthy subjects. Levels of specific antipneumococcal IgG and the mean fold increase in IgG levels at 1 month as well as the kinetics of antibodies along the 12 months in all groups of HIV-infected patients and healthy subjects were similar. Neither CD4 cell count at baseline nor "nadir" CD4 cells correlated with the response to the vaccine. In conclusion, the immunogenicity conferred by the polysaccharide vaccine in HIV-infected patients under HAART is at least as good as that observed in healthy subjects. © 2005 Elsevier Ltd. All rights reserved.

KW - HIV infection

KW - Pneumococcal polysaccharide vaccine

U2 - 10.1016/j.vaccine.2005.12.021

DO - 10.1016/j.vaccine.2005.12.021

M3 - Article

SN - 0264-410X

VL - 24

SP - 2567

EP - 2574

JO - Vaccine

JF - Vaccine

IS - 14

ER -

Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: One year follow-up study

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this